Business Wire

Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that their ongoing pivotal Phase 3 DUPLEX Study of ...
Yahoo Finance

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
MedPage Today

Sparsentan for Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) still lacks an FDA-approved therapy, but late-breaking post hoc results from the phase III DUPLEX trial -- presented at the National Kidney Foundation Spring ...
Newswire

Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

Sparsentan was well-tolerated with a consistent safety profile across all clinical trials conducted to date and comparable to irbesartan "This is a preliminary data picture from the trial, and we will ...
Nasdaq

Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

To date in the study, sparsentan has been generally well-tolerated and has shown a safety profile comparable to irbesartan Company to host conference call and webcast today at 8:30 a.m. ET “For ...